



Neuland Q2 FY21 income at Rs.242.0 crore; up 29.6%

EBITDA margins improve by 350 bps

Hyderabad, India, November 3, 2020 - Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the second quarter (Q2FY21) ended September 30, 2020.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said “We are pleased to report a record quarterly revenue of Rs.242 crores. The revenue growth of 29.6% was powered by both the Prime and CMS verticals. We believe this sets us up firmly on the growth path for the rest of this year while providing a strong base for the next fiscal as well. We are also pleased to report that Unit III has commenced revenue generation which will act as a further tailwind going forward.”

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added “The CMS business is continuing to drive growth with good performance from the baseline projects. We are seeing our efforts over the years pay off as more molecules are progressing in the pipeline towards commercialization. Our focus will continue to be on adding products in both GDS and CMS that will drive long term growth.”

Financial Summary

Particulars	Rs. crore							
	Q2FY21	Q1FY21	QoQ Growth (%)	Q2FY20	YoY Growth (%)	H1FY21	H1FY20	YoY Growth (%)
Total Income	242.0	206.1	17.4%	186.8	29.6%	448.1	368.3	21.7%
EBITDA	41.4	34.4	20.1%	25.4	62.8%	75.8	44.5	70.4%
EBITDA margin (%)	17.1%	16.7%	40 bps	13.6%	350 bps	16.9%	12.1%	480 bps
PAT	21.3	15.1	41.7%	8.6	148.9%	36.4	14.2	156.5%
PAT margin (%)	8.8%	7.3%	150 bps	4.6%	420 bps	8.1%	3.9%	430 bps
EPS (Basic) Rs.	16.63	11.74	41.7%	6.68	148.9%	28.37	11.06	156.5%

Q2 FY21 Earnings Call

The company will conduct a one-hour Earnings call at 17:00 hrs. IST on Tuesday, November 3rd, 2020 where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are +91 22 6280 1107 / +91 22 7115 8008. Other



numbers are listed in the conference call invite which is posted on our website. Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 36 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 898+ Regulatory filings in the US (55 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Diwakar Pingle, Christensen

Email: dpingle@christensenir.com

Jenna Palmieri, Neuland Laboratories Inc., USA

Email: jenna@neulandlabs.com